Study used blood test to identify distinct molecular signatures of disease; paves the way to precision medicine for cystic fibrosis
Researchers at Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago, and colleagues, used a blood test and microarray technology to identify distinct molecular signatures in children with cystic fibrosis. These patterns of gene expression ultimately could help predict disease severity and treatment response, and lead to therapies tailored to each patient’s precise biology. Findings were published in Physiological Genomics.
“Our findings pave the way to precision medicine for cystic fibrosis patients, eventually helping us match treatment to each patient’s unique genomic pattern of disease,” says lead author Hara Levy, MD, MMSc, from Manne Research Institute at Lurie Children’s, who is an Associate Professor of Pediatrics at Northwestern University Feinberg School of Medicine. “Our study was the first to identify molecular signatures of cystic fibrosis from a blood test taken during a routine clinic visit, giving us a baseline. Greater understanding of these molecular signatures may lead to unique molecular markers that could help us intervene earlier to changes in a patient’s inflammatory response to airway infection or pancreatic function, allowing us to provide more focused treatment. It would be a huge improvement over the one-size-fits-all treatment approach we currently have for patients with cystic fibrosis.”
To identify baseline molecular signatures in cystic fibrosis, Dr. Levy’s lab obtained genomic information from patients’ blood samples using cutting-edge technologies such as Affymetric array and Illumina MiSeq. The team then merged this genomic information with each individual’s clinical history gathered from electronic medical records. They compared this snapshot of patient-specific data with healthy controls. Their study provides strong evidence for distinct molecular signatures in cystic fibrosis patients that correlate with clinical outcomes.
Cystic fibrosis is a progressive genetic disease that damages multiple organs, including the lungs and pancreas. Currently, the average predicted survival is 47 years. Although cystic fibrosis is caused by dysfunction of a single gene (CFTR) and treatment that targets CFTR mutations is available, the relationships between the abnormal gene product, development of inflammation and disease progression are not fully understood. This limits the ability to predict a patient’s clinical course, provide individualized treatment and rapidly monitor treatment response.
For example, it is not clear why patients with cystic fibrosis are susceptible to chronic lung infections, since they are considered to have a functional immune system.
“We are now trying to discover why patients with cystic fibrosis become infected so easily,” says Dr. Levy. “We are taking a closer look at the immune cells that make up many of the molecular signatures we found in cystic fibrosis.”
More study is needed before precision medicine for cystic fibrosis reaches the clinic.
“With more research, a blood test to gather genomic specifics of each patient’s disease might be available in the clinic within the next five years,” says Dr. Levy. “Precision medicine will revolutionize care for cystic fibrosis patients.”
The Latest on: Cystic fibrosis
via Google News
The Latest on: Cystic fibrosis
- Charity sushi: Girl’s creation helps fight cystic fibrosis on February 6, 2019 at 3:11 pm
PORTSMOUTH — It's not every six-year-old who has a sushi roll named after them, let alone one they designed themselves. At Shio Japanese Restaurant on Route 1, when both sushi connoisseurs and amateur... […]
- How gymnastics helps P.E.I.'s Canada Games flag bearer live beyond cystic fibrosis on February 6, 2019 at 4:46 am
P.E.I. competitive gymnast Cameron Davis has been living with cystic fibrosis his whole life — he says being physically active through gymnastics allows him to live beyond the limitations of the genet... […]
- Fakenham ukelele group donate ‘amazing’ £500 to cystic fibrosis fundraiser on February 6, 2019 at 2:15 am
Sharon Moore, 47, who runs the Fakenham branch of the Cystic Fibrosis Trust, was presented with a £500 cheque from the Fakenham Ukeleles. Ukeleles leader Graham Thomas, along with other members of the ... […]
- Cystic fibrosis sufferer slams the NHS after being denied funding for IVF and surrogacy on February 5, 2019 at 11:41 pm
A cystic fibrosis sufferer who is unable to have children has slammed the NHS for denying her funding for IVF and surrogacy. Sophie Gannon, 30, who has already had a double lung transplant, has been t... […]
- Cystic fibrosis researchers make advancements in treatment at the U of S on February 5, 2019 at 1:35 pm
A medical research team at the University of Saskatchewan hopes to make a commonly used treatment for cystic fibrosis (CF) more effective and tolerable. They say that could be the result of a ... […]
- Cystic fibrosis sufferer, 3, begs NHS for drugs that will save her life on February 5, 2019 at 7:19 am
Little Ayda Louden suffers with the debilitating illness that shortens life by causing lung damage, diabetes and liver disease. The average life expectancy for the genetic disease is just 31. But a ne... […]
- Four-year-old cystic fibrosis sufferer may have to move to Scotland to get access to a 'wonder drug' on February 4, 2019 at 10:25 pm
The family of a girl battling cystic fibrosis (CF) face the difficult decision of whether to uproot and move to Scotland in the hope they will have access to a 'wonder drug' that could prolong her lif... […]
- UC Berkeley professor collaborates on study to improve cystic fibrosis treatment on February 4, 2019 at 9:10 pm
UC Berkeley professor Terry Machen is collaborating with researchers from Canada to discover new treatments for cystic fibrosis, an incurable genetic disease that cuts decades off the lives of patient... […]
- ‘We’re still waiting’: As cystic fibrosis drugs deliver new hope, not everyone is being swept up by scientific progress on February 4, 2019 at 10:39 am
CAMBRIDGE, Mass. — The tiny round one is vitamin K. There’s a gel cap (vitamin D), a two-tone capsule (that one protects his liver), a square pill (generic Singulair), and more — seven pill bottles sh... […]
- 'Deadlock must end' over cystic fibrosis drug Orkambi on February 4, 2019 at 9:41 am
The government must use its powers to break a deadlock in making a life-extending drug available to people with cystic fibrosis, campaigners say. Vertex, which makes Orkambi, has refused a £500m offer ... […]
via Bing News